Elecsys® Anti-HAV II

Immunoassay for the qualitative detection of total antibodies against hepatitis A virus (HAV)

Elecsys pack
Immunoassay for the qualitative detection of total antibodies against hepatitis A virus (HAV)

Elecsys® Anti-HAV II is an immunoassay for the in vitro qualitative detection of total (IgM and IgG) antibodies to HAV in human serum and plasma. It is used as an aid to detect a past or existing HAV infection or to determine the presence of antibody response to HAV in vaccine recipients.12


Hepatitis A


Hepatitis A is an acute, inflammatory liver disease caused by infection with HAV. HAV is a non-enveloped RNA virus in the family of Picornaviridae (genus Hepatovirus). Three genotypes and 6 subgenotypes of human HAV have been described based on the variability of the capsid gene. However, only one single serotype of the human HAV has been identified.1-5

Hepatitis A occurs sporadically and in epidemics worldwide, with around 1.5 million new clinically recognized HAV infections.3,4 HAV is transmitted fecal-orally either by person-to-person contact or ingestion of contaminated food or water in regions of low hygienic standards. Cooked foods can transmit HAV if the temperature during food preparation is inadequate to inactivate the virus or if food is contaminated through infected food handlers.1,4-6

HAV has only been linked with acute hepatitis, and most patients fully recover within two months after infection. Only 10 - 15 % of people infected will have prolonged or relapsed illness for up to 6 months. Exposure to HAV creates lifelong immunity against future infection. HAV vaccines are available, which also stimulate active, lifelong immunity with 95 – 100 % efficiency.1-4

Anti-HAV IgM becomes detectable 5 - 10 days before onset of symptoms, peaks during the symptomatic period and becomes undetectable in 75 % of patients 3 - 6 months after infection. Anti-HAV IgG, which appears after IgM, begins to rise at or right before the onset of clinical illness, peaks during the convalescent period, and persists to provide lifelong protection against the disease.3,7-11

Proposed algorithms for diagnosis of HAV infection

Unkown HAV immune status

  • The patient may have an acute or past HAV infection, or may not be immune
  • Initial test – anti-HAV total assay
Algorithm 1

With this algorithm, all three possible outcomes can be identified by testing first with the anti-HAV total assay followed by the anti-HAV IgM assay if necessary. By contrast, an anti-HAV IgG assay alone cannot identify or exclude acute infection; an anti-HAV IgM test is also required.10,14

Suspected acute HAV infection

  • The patient is exhibiting clinical symptoms
  • Initial test – anti-HAV IgM assay
Algorithm 2

With this algorithm, all three possible outcomes can be clearly identified by testing first with the anti-HAV IgM assay followed by the anti-HAV total assay if necessary.10,14,15

Marker profile

Hepatitis A infection marker profile after natural infection3,7-10,13



  1. Van Damme P, et al. Hepatitis A virus infection. Nature Rev Dis Prim. 2023; 9:51.
  2. Lemon SM, et al. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol. 2018;68:167-184.
  3. Pischke S, Wedemeyer H. Hepatitis C. In: Mauss S, et al. (eds.). Hepatology - A Clinical Textbook; 10th Edition [Internet; updated 2020; cited 2024 May 13]. Available from: www.hepatologytextbook.com.
  4. World Health Organization (WHO). Hepatitis A Factsheet [Internet; updated 2023 Jul 20; cited 2024 May 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a.
  5. Yong HT, Son R. Hepatitis A virus - a general overview. Int Food Res J. 2009;16:455-467.
  6. Centers for Disease Control and Prevention (CDC). Clinical Overview of Hepatitis A [Internet; updated 2024 Jan 11; cited 2024 May 13]. Available from: https://www.cdc.gov/hepatitis-a/hcp/clinical-overview.
  7. Hollinger FB, Emerson SU. Hepatitis A virus. In: Knipe OM, Howley PM, editors. Fields Virology, 5th edition. Lippincott Williams and Wilkins, Philadelphia: 2007.
  8. Stapleton JT. Host Immune Response to Hepatitis A Virus. J Inf Dis. 1995;171(suppl 1):89-14.
  9. Roque-Afonso AM, et al. Hepatitis A virus: serology and molecular diagnostics. Future Virol. 2010;5:233-242.
  10. Salete de Paula V. Laboratory diagnosis of hepatitis A. Future Virol. 2012;7:461-472.
  11. Pondé, RA. The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited. Arch Virol. 2017;162:3587-3602.
  12. Elecsys Anti-HAV II method sheets. Mat. No. 08086630190 V3.0, 2023-12;, Mat. No. 08086664190 V5.0, 2021-12.
  13. Centers for Disease Control and Prevention (CDC). Viral Hepatitis Serology Training, Hepatitis A [Internet; 2015 Nov 25; cited 2024 May 13]. Available from: https://www.cdc.gov/hepatitis/resources/professionals/training/serology/training.htm.
  14. Gilson R, Brook MG. Hepatitis A, B, and C. Sex Transm Infect. 2006;82(Suppl 4):iv35-iv39.
  15. Public Health England. UK Standards for Microbiology Investigations - Hepatitis A virus acute infection serology [Internet; updated 2019 Jan 18; cited 2024 May 13]. Available from: https://www.rcpath.org/static/8c7fd037-8032-4750-a47ded258e136108/uk-smi-v-27i4-hepatitis-a-virus-acute-infection-serology-january-2019-pdf.pdf.

Elecsys® Anti-HAV II

  • Testing Time

    18 minutes

  • Test principle

    Inverted 2-step competitive assay

  • Calibration


  • Interpretation

    COI >1.0 = non-reactive (negative for HAV-specific antibodies)
    COI ≤1.0 = reactive (positive for HAV-specific antibodies)
















  • Traceability

    Traceable to the “Second International Standard for Anti‑Hepatitis A, immunoglobulin, human”, NIBSC code 97/646 of the NIBSC (National Institute for Biological Standards and Control) via method comparison to the first generation Elecsys® Anti‑HAV assay as reference.








  • Sample material

    Serum collected using standard sampling tubes or tubes containing separating gel.
    Li‑heparin, Na‑heparin, K2‑EDTA, K3‑EDTA, ACD, CPD, CP2D, CPDA and Na‑citrate plasma. Plasma tubes containing separating gel can be used.

  • Sample volume

    20 μL cobas e 411 analyzer, cobas e 601 / cobas e 602 modules
    12 μL cobas e 402 / cobas e 801 analytical units















  • Onboard stability

    8 week cobas e 411 analyzer, cobas e 601 / cobas e 602 modules
    16 weeks cobas e 402 / cobas e 801 analytical units











  • Intermediate precision in positive samples

    cobas e 411 analyzer: CV 1.3 - 3.2%
    cobas e 601 / cobas e 602 modules: CV 1.8 - 3.3%
    cobas e 402 / cobas e 801 analytical units: CV 2.0 - 3.5%

  • Relative sensitivity

    Subjects vaccinated against hepatitis A (N = 238): 100 % (99.45 – 100 %*)
    Subjects with acute hepatitis A infection (N = 234): 100 % (98.44 – 100 %)
    Subjects recovered from hepatitis A infection (N = 256): 100 % (98.57 – 100 %)








  • Relative specificity

    Blood donors (N = 577): 99.48 % (98.49 – 99.89 %)
    Subjects with routine request for anti‑HAV testing (N = 871): 99.66 % (99.00 – 99.93 %)

* 95 % confidence interval (2-sided)